| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | CD79B | Synonyms | AGM6, B29, IGB, Igbeta | Type of gene | protein-coding |
| Chromosome | 17 | Map location | 17q23.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | CD79b molecule | ||||
| GTO ID | GTC3091 |
| Trial ID | NCT05436509 |
| Disease | B-Cell Malignancy |
| Altered gene | CD19|CD79b |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | bi-4SCAR CD19/79b T cells |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | CD19/79b Bi-specific CAR-T Cell Therapy |
| Year | 2022 |
| Country | China |
| Company sponsor | Shenzhen Geno-Immune Medical Institute |
| Other ID(s) | GIMI-IRB-22009 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||
|
|||||||||